Abstract Number: L12 • ACR Convergence 2023
Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis
Background/Purpose: TYK2 mediates signaling by key cytokines involved in the pathogenesis of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA) and psoriasis (PsO). TAK-279 is…Abstract Number: 0202 • ACR Convergence 2023
Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)
Background/Purpose: The importance and efficacy of mRNA COVID-19 vaccination in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…Abstract Number: 0491 • ACR Convergence 2023
Arthralgia with Risk of Progression to Psoriatic Arthritis in a Large Cohort of Patients: Role of Ultrasound
Background/Purpose: The psoriasis- to- psoriatic arthritis (PsA) transition offers a unique opportunity to identify individuals at increased risk of developing PsA and to implement preventive…Abstract Number: 0507 • ACR Convergence 2023
The Use of PSAID-12 in Remote Monitoring Correlates with In-person Clinical Examination Findings in Psoratic Arthritis
Background/Purpose: Patient-reported outcome measures (PROMs) are important tools for evaluating disease activity, functional status, and quality of life in patients with psoriatic arthritis (PsA). The…Abstract Number: 0966 • ACR Convergence 2023
The Burden of Oligoarticular Psoriatic Arthritis in the United States
Background/Purpose: Patients with oligoarticular psoriatic arthritis (oligo PsA), defined as four or less joints involved, often do not meet criteria for entry in trials of…Abstract Number: 1413 • ACR Convergence 2023
Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients with Early Oligoarticular Psoriatic Arthritis: 16-Week Results from FOREMOST
Background/Purpose: The modified minimal disease activity (MDA-Joints) is a novel composite endpoint to assess disease activity and treatment effect in PsA based on a criteria…Abstract Number: 1430 • ACR Convergence 2023
A Proof-of-concept Study Evaluating the Use of Functional Brain Magnetic Resonance Imaging in Assessing Treatment Response in Psoriatic Arthritis Patients
Background/Purpose: Inflammatory cytokines can alter the way the central nervous system processes pain as shown in patients with rheumatoid arthritis. However, the relationship between TNFα…Abstract Number: 1644 • ACR Convergence 2023
The EISER Study: Identifying Microbial Factors Associated with Subclinical Gut Inflammation in Spondyloarthritis Patients
Background/Purpose: Nearly 8% of patients with spondyloarthritis (SpA) manifest symptoms that are compatible with active inflammatory bowel disease (IBD), despite not having any previous diagnosis…Abstract Number: 1815 • ACR Convergence 2023
The Association of Body Mass Index with SARS-CoV-2 Infection (COVID-19) in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Background/Purpose: To determine the association of body mass index (BMI) with incident COVID-19 infection in patients with inflammatory arthritis (IA) using biologic disease-modifying anti-rheumatic drugs…Abstract Number: 2236 • ACR Convergence 2023
Guselkumab Provides Rapid Clinically Meaningful Improvements in Clinical and Patient Reported Outcomes and Sustained Disease Control of Psoriatic Arthritis
Background/Purpose: Guselkumab (GUS) has demonstrated robust efficacy across key PsA domains at Week (W) 24, with effects sustained or further enhanced through 2 years. Timing…Abstract Number: 2252 • ACR Convergence 2023
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomized Study
Background/Purpose: PsA is a chronic disease affecting multiple domains; however, patients (pts) can experience loss of response with long-term therapy.1 Therefore, maintaining long-term treatment responses…Abstract Number: 0327 • ACR Convergence 2023
Self-management Strategies and Self-efficacy in Patients Living with Inflammatory Arthritis: Findings from a Quality Improvement Project in a Tertiary Centre
Background/Purpose: The 2021 EULAR guidelines on self-management have made recommendations (rec) to aid with the implementation of self-management strategies in inflammatory arthritis (IA) (1). Their…Abstract Number: 0492 • ACR Convergence 2023
Axial Spondyloarthritis in Patients with Late-Onset Chronic Low Back Pain (Older Than 45 Years). Axial Spa or Psoriatic Disease with Axial Involvement?
Background/Purpose: It is known that patients diagnosed with axSpA do not subsequently meet the classification criteria. The Objectives are: To estimate the diagnostic prevalence of…Abstract Number: 0508 • ACR Convergence 2023
Assessment of Pain Outcomes in a Phase 2 Trial of a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active PsA
Background/Purpose: Pain is commonly cited by patients with PsA as affecting their daily activities and quality of life and may differ by sex1. In addition…Abstract Number: 0981 • ACR Convergence 2023
Time Trends in Overall Infection Risk in Patients with Inflammatory Arthritides Treated with Tumor Necrosis Factor Inhibitors
Background/Purpose: Infections are a known complication of disease-modifying therapy in rheumatic patients but have also been associated with the diseases being treated. Biosimilars have increased…
- 1
- 2
- 3
- …
- 70
- Next Page »